Predictive stratification of HSPC sufferers based mostly on prostate-specific antigen (PSA), C-reactive protein (CRP), miR-375, AR gene amplification, platelets, and chromogranin A. Credit score: The Journal of Molecular Diagnostics (2025). DOI: 10.1016/j.jmoldx.2025.02.006
New analysis has recognized particular blood-based biomarkers that may predict the failure of prostate most cancers remedy in each hormone-sensitive and castration-resistant sufferers. The research revealed in The Journal of Molecular Diagnostics identifies platelets, C-reactive protein, and chromogranin A as necessary indicators in hormone-sensitive prostate most cancers sufferers for the mixed androgen deprivation and androgen receptor pathway inhibitor remedy failure to information alternate remedy.
Probably the most prevalent cancers, prostate most cancers is characterised by its vital heterogeneity, metastatic tendencies, and remedy resistance. The illness sometimes evolves in a hormonal-dependent method, initially categorized as hormone-sensitive prostate most cancers, with remedy methods targeted on decreasing androgen ranges, the first drivers of prostate most cancers development. This technique displays restricted efficacy over time and in the end fails.
Lead investigator Jan Bouchal, Ph.D., Division of Medical and Molecular Pathology, Institute of Molecular and Translational Drugs, Palacký College and College Hospital Olomouc, Olomouc, Czechia, says, “Androgen deprivation remedy has lengthy been the first-line remedy for hormone-sensitive prostate most cancers.
“Recently, combined therapy with androgen deprivation therapy and androgen receptor pathway inhibitors has been recommended for metastatic hormone-sensitive prostate cancer patients. To monitor the disease and optimize outcomes for these patients, oncologists need new or re-established markers.”
On this research, plasma samples have been collected from 140 sufferers with both metastatic hormone-sensitive (N=72) or castration-resistant (N=68) prostate most cancers earlier than the beginning of androgen receptor pathway inhibitors remedy. Digital PCR was used to evaluate androgen receptor (AR) gene amplification, whereas the expression ranges of microRNA (miR)-375 have been measured by quantitative PCR.
Sixteen different scientific markers have been additionally evaluated, together with prostate particular antigen (PSA), chromogranin A (CGA), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), C-reactive protein (CRP), lymphocyte-to-monocyte ratio (LMR), and platelets.
Co-lead investigator Hana Študentová, Ph.D., Division of Oncology, Palacký College and College Hospital Olomouc, Olomouc, Czechia, explains, “A multivariate evaluation, adjusted for age and metastatic dissemination, recognized miR-375 expression and LMR to be the one impartial damaging predictors for androgen receptor pathway inhibitors remedy failure in castration-resistant prostate most cancers sufferers.
“Regarding the hormone-sensitive prostate cancer patients, we report the priority finding on the independent negative predictive value of platelets, CRP, and CGA for the therapy failure of the combined androgen deprivation therapy and androgen receptor pathway inhibitors. Monitoring these biomarkers can provide crucial insights into disease progression and potential therapy failure, enabling more timely and personalized therapeutic interventions.”
The invention of platelet counts as an impartial damaging predictive issue for hormone-sensitive prostate most cancers handled with the mixed androgen deprivation remedy and androgen receptor pathway inhibitors is particularly necessary in mild of latest analysis that emphasizes the important position of platelets in selling the expansion of current metastases.
This analysis demonstrates that platelets play a twin position in metastasis development. They assist within the preliminary phases of metastasis by binding to tumor cells, they usually additionally assist the survival and development of established metastatic tumors by suppressing the immune response.
Dr. Bouchal concludes, “Analysis of platelets, CRP, and CGA is established in lots of laboratories and may simply be exploited for the care of sufferers with metastatic hormone-sensitive prostate most cancers. Our research validates the utility of blood-based biomarkers in predicting remedy outcomes for sufferers with each sorts of prostate most cancers.
Extra data:
Eva Chrenková et al, Platelets, Chromogranin A, and C-Reactive Protein Predict Remedy Failure of Metastatic Hormone-Delicate Prostate Most cancers whereas miR-375 Outperforms Prostate-Particular Antigen in Stratifying Castration-Resistant Prostate Most cancers, The Journal of Molecular Diagnostics (2025). DOI: 10.1016/j.jmoldx.2025.02.006
Quotation:
Novel evaluation identifies markers which will predict failure of metastatic prostate most cancers remedy (2025, Might 12)
retrieved 12 Might 2025
from https://medicalxpress.com/information/2025-05-analysis-markers-failure-metastatic-prostate.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
